Publications by authors named "Hui-Shan Su"
Article Synopsis
- Hypoxia contributes to the development of hepatocellular carcinoma (HCC) but also presents opportunities for treatment using hypoxia-activated prodrugs (HAPs), like TH-302.* -
- The study focuses on creating a hypoxia-activated antibody (HAP103) targeting a specific form of pyruvate kinase (PKM2) to improve treatment effectiveness and reduce side effects compared to traditional antibodies.* -
- HAP103 demonstrated selective targeting and significant tumor-inhibitory activity in HCC mouse models, showing potential for synergistic effects with TH-302 while minimizing toxicity, making it a promising advancement in targeted cancer therapy.*
Therapeutic antibodies (Abs) improve the clinical outcome of cancer patients. However, on-target off-tumor toxicity limits Ab-based therapeutics. Cluster of differentiation 147 (CD147) is a tumor-associated membrane antigen overexpressed in cancer cells.
View Article and Find Full Text PDF